Hypericin Combination Therapy for Antiviral Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Small molecule antiviral agents used to treat viral infections often present harmful side effects due to toxicity, necessitating an improvement in their clinical profile.
Innovation Solution
A combination therapy involving a hypericin compound and an antiviral agent, such as remdesivir or sofosbuvir, is administered to enhance efficacy and reduce toxicity, with the hypericin compound being present in greater molar amounts than the antiviral agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule antiviral agents are used to treat viral infections, then viral infection is treated, but harmful side effects and toxicity occur
Solution Approach 1:
The patent introduces a second antiviral agent as an intermediary that modulates the interaction between the first antiviral agent and the virus. This intermediary agent reduces the toxicity of the first agent while maintaining or enhancing its antiviral efficacy, effectively mediating the harmful effects without compromising the primary treatment function
Solution Approach 2:
The patent employs a composite therapeutic approach by combining two different antiviral agents with distinct mechanisms of action. This composite therapy leverages the synergistic effects of both agents to achieve improved antiviral efficacy at lower doses, thereby reducing the toxicity associated with high-dose monotherapy while maintaining reliable treatment outcomes
2Reliability
If higher doses of antiviral agents are administered, then efficacy increases, but toxicity increases
Solution Approach 1:
The patent changes the dosing parameters by administering two antiviral agents at optimized, lower individual doses rather than one agent at a high dose. This parameter modification achieves the same or better therapeutic effect while reducing the toxicity burden, as each agent contributes to the overall efficacy at manageable dose levels
Data Source
AI summary
The present disclosure relates to therapeutic agents and combinations thereof (e.g., pharmaceutical compositions) for the treatment of a viral infection in a subject, tissue or cell.